Jazz Pharmaceuticals’ Cozadd exercises 86,500 options

Q: How many JAZZ stock options did Bruce C. Cozadd exercise, and at what price?

Bruce C. Cozadd exercised options covering 86,500 Jazz Pharmaceuticals ordinary shares on November 6, 2026, at $136.18 per share. The options comprised 734 incentive stock options and 85,766 non-qualified stock options.

Q: How many JAZZ shares did Bruce C. Cozadd sell, and at what prices?

He sold 68,808 ordinary shares in four transactions on November 6, 2026. The reported weighted-average sale prices were $234.9122 for 27,714 shares, $235.8220 for 10,688, $236.8440 for 24,483, and $237.3869 for 5,923.

The broker-assisted sales covered the options’ aggregate exercise price and applicable tax withholding obligations.

Available on EDGAR 11/10/2026 - 04:46 PM EST Accepted by SEC EDGAR 11/10/2026 - 04:46 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Jazz Pharmaceuticals plc director Bruce C. Cozadd exercised 86,500 stock options on November 6, 2026, at an exercise price of $136.18 per share, acquiring ordinary shares. He sold 68,808 shares in four broker-assisted sell-to-cover transactions at weighted-average prices from $234.9122 to $237.3869 per share. The options were fully vested and scheduled to expire March 1, 2027; the sales covered the aggregate exercise price and applicable tax withholding, and he retained all remaining acquired shares. No Rule 10b5-1 plan is reported.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 8 txns

Insider COZADD BRUCE C

Role Director

Sold 68,808 shs ($16.24M)

Approx. gross sale proceeds $16.24M

Approx. exercise cost $11.78M

Share of Position Sold 16.1%

Type	Security	Shares	Price	Value
Exercise	Incentive Stock Option (right to buy) ^{F6, F7}	734	$0.00	$0.00
Exercise	Non-Qualified Stock Option (right to buy) ^{F6, F7}	85,766	$0.00	$0.00
Exercise	Ordinary Shares	734	$136.18	$100K
Exercise	Ordinary Shares	85,766	$136.18	$11.68M
Sale	Ordinary Shares ^{F1, F2}	27,714	$234.9122	$6.51M
Sale	Ordinary Shares ^{F1, F3}	10,688	$235.822	$2.52M
Sale	Ordinary Shares ^{F1, F4}	24,483	$236.844	$5.80M
Sale	Ordinary Shares ^{F1, F5}	5,923	$237.3869	$1.41M

Holdings After Transaction: Incentive Stock Option (right to buy) — 0 options (Direct); Non-Qualified Stock Option (right to buy) — 0 options (Direct); Ordinary Shares — 357,567 shares (Direct)

Holdings Before and After: Incentive Stock Option (right to buy), 734 to 0 options (Direct); Non-Qualified Stock Option (right to buy), 85,766 to 0 options (Direct); Ordinary Shares, 339,875 to 357,567 shares (Direct)

Other Insiders: 2 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (7)

F1. The sales of ordinary shares reported on this Form 4 were effected pursuant to a broker-assisted sell-to-cover exercise of fully vested stock options scheduled to expire on March 1, 2027. The ordinary shares were sold solely to cover the aggregate exercise price and applicable tax withholding obligations. The Reporting Person retained all remaining ordinary shares acquired upon exercise.
F2. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $234.2650 to $235.2350. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F3. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $235.2700 to $236.2400. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F4. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $236.2900 to $237.2600. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F5. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $237.2900 to $237.7600. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F6. Exercise of stock options before their expiration date.
F7. These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 2, 2017, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter.

Key Figures

Options exercised: 86,500 shares Exercise price: $136.18 per share Ordinary shares sold: 68,808 shares +4 more

7 metrics

Options exercised 86,500 shares November 6, 2026

Exercise price $136.18 per share Options exercised November 6, 2026

Ordinary shares sold 68,808 shares November 6, 2026

Weighted-average sale price 27,714 shares at $234.9122 per share Sale transaction on November 6, 2026

Weighted-average sale price 10,688 shares at $235.8220 per share Sale transaction on November 6, 2026

Weighted-average sale price 24,483 shares at $236.8440 per share Sale transaction on November 6, 2026

Weighted-average sale price 5,923 shares at $237.3869 per share Sale transaction on November 6, 2026

Key Terms

sell-to-cover exercise, weighted average sale price, fully vested stock options, applicable tax withholding obligations

4 terms

sell-to-cover exercise financial

"broker-assisted sell-to-cover exercise of fully vested stock options"

weighted average sale price financial

"The price reported reflects the weighted average sale price."

fully vested stock options financial

"fully vested stock options scheduled to expire on March 1, 2027"

applicable tax withholding obligations financial

"the aggregate exercise price and applicable tax withholding obligations"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many JAZZ stock options did Bruce C. Cozadd exercise, and at what price?

Bruce C. Cozadd exercised options covering 86,500 Jazz Pharmaceuticals ordinary shares on November 6, 2026, at $136.18 per share. The options comprised 734 incentive stock options and 85,766 non-qualified stock options.

How many JAZZ shares did Bruce C. Cozadd sell, and at what prices?

He sold 68,808 ordinary shares in four transactions on November 6, 2026. The reported weighted-average sale prices were $234.9122 for 27,714 shares, $235.8220 for 10,688, $236.8440 for 24,483, and $237.3869 for 5,923.

Why did Bruce C. Cozadd sell JAZZ shares?

The sales were effected through a broker-assisted sell-to-cover exercise, solely to cover the aggregate exercise price and applicable tax withholding obligations. Cozadd retained all remaining ordinary shares acquired upon exercise. The options were scheduled to expire March 1, 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

COZADD BRUCE C

(Last)

(First)

(Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4

(City)

(State)

(Zip)

IRELAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	11/06/2026		M		734	A	$136.18	340,609	D
Ordinary Shares	11/06/2026		M		85,766	A	$136.18	426,375	D
Ordinary Shares	11/06/2026		S		27,714⁽¹⁾	D	$234.9122⁽²⁾	398,661	D
Ordinary Shares	11/06/2026		S		10,688⁽¹⁾	D	$235.822⁽³⁾	387,973	D
Ordinary Shares	11/06/2026		S		24,483⁽¹⁾	D	$236.844⁽⁴⁾	363,490	D
Ordinary Shares	11/06/2026		S		5,923⁽¹⁾	D	$237.3869⁽⁵⁾	357,567	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Incentive Stock Option (right to buy)	$136.18	11/06/2026		M			734⁽⁶⁾	⁽⁷⁾	03/01/2027	Ordinary Shares	734	$0.0	0	D
Non-Qualified Stock Option (right to buy)	$136.18	11/06/2026		M			85,766⁽⁶⁾	⁽⁷⁾	03/01/2027	Ordinary Shares	85,766	$0.0	0	D

Explanation of Responses:

1. The sales of ordinary shares reported on this Form 4 were effected pursuant to a broker-assisted sell-to-cover exercise of fully vested stock options scheduled to expire on March 1, 2027. The ordinary shares were sold solely to cover the aggregate exercise price and applicable tax withholding obligations. The Reporting Person retained all remaining ordinary shares acquired upon exercise.

2. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $234.2650 to $235.2350. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

3. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $235.2700 to $236.2400. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

4. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $236.2900 to $237.2600. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

5. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $237.2900 to $237.7600. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

6. Exercise of stock options before their expiration date.

7. These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 2, 2017, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter.

	By: /s/Paz Dizon, as attorney in fact For: Bruce C. Cozadd	11/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR